Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients

Transplant Infectious Disease

Volumn 15, Issue 2, 2013, Pages 171-180

  Katsolis, J G ^a   Bosch, W ^a   Heckman, M G ^a   Diehl, N N ^a   Shalev, J A ^a   Pungpapong, S ^a   Gonwa, T A ^a   Hellinger, W C ^a  

^a MAYO CLINIC   (United States)

Author keywords

CMV donor seropositive (D+); CMV recipient seronegative (R ); Cytomegalovirus (CMV); High risk; Liver transplantation; Risk factors

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BILIRUBIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; GENDER; GRAFT FAILURE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OPERATION DURATION; ORGAN DONOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84875940364     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12050     Document Type: Article

References (12)

1. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14 (31): 4849-4860.
2. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18 (2): 185-195.
3. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78 (9): 1390-1396.
4. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81 (12): 1645-1652.
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transplant 2007; 13 (12): 1703-1709.
6. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350 (9093): 1729-1733.
7. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184 (11): 1461-1464.
8. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11 (10): 2181-2189.
9. [No authors listed.] Cytomegalovirus. Am J Transplant 2004; 4 (Suppl 10): 51-58.
10. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
11. Freeman RB, Paya C, Pescovitz MD, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78 (12): 1765-1773.
12. Kotton CN. Preventative tools of the future: predicting the individual risk of cytomegalovirus infection after transplant. Transplantation 2012; 93: 467-468.